Emerging treatments
Ibritumomab tiuxetan
A CD20-directed radiotherapeutic antibody. In a small single-arm, single-center, phase 2 clinical trial, an overall response rate of 94% (and complete response rate of 62.5%) was reported in patients with newly diagnosed or relapsed/refractory MALT lymphoma who received ibritumomab tiuxetan.[63]
Axicabtagene ciloleucel
An anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. In a single-arm phase 2 trial, an overall response rate of 92% (and complete response rate of 74%) was reported in patients with relapsed/refractory indolent non-Hodgkin lymphoma (including follicular lymphoma and marginal zone lymphoma).[64]
Acalabrutinib
A covalent Bruton tyrosine kinase (BTK) inhibitor. In an open-label phase 1b/2 trial, acalabrutinib-treated patients with relapsed/refractory marginal zone lymphoma had an overall response rate of 53% (and complete response rate of 13%).[65]
Pirtobrutinib
A noncovalent BTK inhibitor. In a phase 1/2 trial of heavily pretreated patients with relapsed/refractory marginal zone lymphoma, treatment with pirtobrutinib was associated with an overall response rate of 50% (and complete response rate of 2.8%).[66]
Use of this content is subject to our disclaimer